Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB19 hours ago · The health regulator has cleared the drug's use as an add-on treatment for some adults with inadequately controlled chronic obstructive pulmonary disease (COPD), a condition that progressively ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB19 hours ago · After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB19 hours ago · Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Following recent approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEBDupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be …
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive ...
WEB18 hours ago · Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease RTTNews 3h Press Release: Dupixent approved in China as the first-ever biologic medicine for ...
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEBWith the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to …
Dupixent® (dupilumab) Approved in China as the First-ever …
WEBTARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the National Medical Products Administration (NMPA) in China has approved Dupixent ® (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD ...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB16 hours ago · The asset is tailored towards patients with moderate-to-severe exacerbations with chronic obstructive pulmonary disease (COPD), as an add-on maintenance treatment for uncontrolled COPD ...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBMay 31, 2024 · The primary endpoint was met in both trials, showing Dupixent significantly reduced annualized moderate or severe acute COPD exacerbations by up to 34%, compared to placebo. Dupixent rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
WEB12 hours ago · Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
Skip to content